186 related articles for article (PubMed ID: 35713152)
1. Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.
Zhang C; Lu Y; Song Y; Chen L; Hu J; Meng Y; Chen X; Li S; Zheng G; Qiu Z
J Cell Mol Med; 2022 Jul; 26(14):3995-4006. PubMed ID: 35713152
[TBL] [Abstract][Full Text] [Related]
2. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
[TBL] [Abstract][Full Text] [Related]
3. Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.
Lu Y; Zhang C; Song Y; Chen L; Chen X; Zheng G; Yang Y; Cao P; Qiu Z
Eur J Pharmacol; 2023 Feb; 940():175457. PubMed ID: 36529278
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Qiu Z; Zhang C; Zhou J; Hu J; Sheng L; Li X; Chen L; Li X; Deng X; Zheng G
Mol Carcinog; 2019 Jan; 58(1):31-41. PubMed ID: 30182439
[TBL] [Abstract][Full Text] [Related]
5. Caffeine Ameliorates AKT-Driven Nonalcoholic Steatohepatitis by Suppressing
Tan X; Sun Y; Chen L; Hu J; Meng Y; Yuan M; Wang Q; Li S; Zheng G; Qiu Z
J Agric Food Chem; 2022 May; 70(20):6108-6122. PubMed ID: 35536225
[TBL] [Abstract][Full Text] [Related]
6. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.
Softic S; Cohen DE; Kahn CR
Dig Dis Sci; 2016 May; 61(5):1282-93. PubMed ID: 26856717
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Chi X; Qu N; Wang C
Biochem Biophys Res Commun; 2018 Apr; 499(1):66-70. PubMed ID: 29555473
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein A4 Restricts Diet-Induced Hepatic Steatosis via SREBF1-Mediated Lipogenesis and Enhances IRS-PI3K-Akt Signaling.
Cheng C; Liu XH; He J; Gao J; Zhou JT; Fan JN; Jin X; Zhang J; Chang L; Xiong Z; Yu J; Li S; Li X
Mol Nutr Food Res; 2022 Sep; 66(18):e2101034. PubMed ID: 35909347
[TBL] [Abstract][Full Text] [Related]
9. Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of Akt.
Kenerson HL; Subramanian S; McIntyre R; Kazami M; Yeung RS
PLoS One; 2015; 10(2):e0117000. PubMed ID: 25646773
[TBL] [Abstract][Full Text] [Related]
10. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
11. Ellagitannins-Derived Intestinal Microbial Metabolite Urolithin A Ameliorates Fructose-Driven Hepatosteatosis by Suppressing Hepatic Lipid Metabolic Reprogramming and Inducing Lipophagy.
Zhang C; Song Y; Yuan M; Chen L; Zhang Q; Hu J; Meng Y; Li S; Zheng G; Qiu Z
J Agric Food Chem; 2023 Mar; 71(9):3967-3980. PubMed ID: 36825491
[TBL] [Abstract][Full Text] [Related]
12. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease.
Ter Horst KW; Serlie MJ
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28878197
[TBL] [Abstract][Full Text] [Related]
13. Fructose-induced perturbation in cellular proteostasis via RPS6KB1 promotes hepatic steatosis.
Raza S; Shahi A; Medhe P; Tewari A; Gupta P; Rajak S; Chakravarti B; Sinha RA
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119597. PubMed ID: 37741573
[TBL] [Abstract][Full Text] [Related]
14. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis.
DeBosch BJ; Chen Z; Saben JL; Finck BN; Moley KH
J Biol Chem; 2014 Apr; 289(16):10989-10998. PubMed ID: 24519932
[TBL] [Abstract][Full Text] [Related]
15. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.
Zhang C; Sheng L; Yuan M; Hu J; Meng Y; Wu Y; Chen L; Yu H; Li S; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2020 Apr; 392():114918. PubMed ID: 32045588
[TBL] [Abstract][Full Text] [Related]
16. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
[TBL] [Abstract][Full Text] [Related]
17. Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis.
Singh A; Ansari A; Gupta J; Singh H; Jagavelu K; Sashidhara KV
Phytomedicine; 2024 Jul; 129():155702. PubMed ID: 38749344
[TBL] [Abstract][Full Text] [Related]
18. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
Benhamed F; Denechaud PD; Lemoine M; Robichon C; Moldes M; Bertrand-Michel J; Ratziu V; Serfaty L; Housset C; Capeau J; Girard J; Guillou H; Postic C
J Clin Invest; 2012 Jun; 122(6):2176-94. PubMed ID: 22546860
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
[TBL] [Abstract][Full Text] [Related]
20. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
